Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/neu.2021.0064 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Relationship Between Posttraumatic Headache and Depression After Mild Traumatic Brain Injury.
J Neuropsychiatry Clin Neurosci
August 2024
Department of Psychiatry and Behavioral Health, Pennsylvania State University College of Medicine, Hershey (Beal); Department of Pediatrics (Psoter), Department of Physical Medicine and Rehabilitation (Bechtold), and Department of Psychiatry and Behavioral Sciences (Peters, Rao, Roy), Johns Hopkins University School of Medicine, Baltimore; Johns Hopkins University Krieger School of Arts and Sciences, Baltimore (Nagpaul); Neurological Diseases, BRAINBox Solutions, Richmond, Virginia (Van Meter); Department of Computational Medicine and Bioinformatics (Falk) and Department of Emergency Medicine (Korley), University of Michigan Medical School, Ann Arbor.
Objectives: Mild traumatic brain injury (mTBI) can lead to psychiatric and somatic symptoms for some patients, including posttraumatic headache (PTH) and depression. This study attempted to further establish the relationship between PTH and depression following mTBI and investigate whether the presence of PTH immediately following injury can identify patients at risk for developing depressive symptoms up to 6 months later.
Methods: This study was a secondary analysis of data from Head Injury Serum Markers for Assessing Response to Trauma (HeadSMART), a prospective study of adult patients in the emergency department with head injury.
The Dangers of Distracted Driving: A Substudy of Patient Perception Data From the DRIVSAFE Observational Study.
J Orthop Trauma
October 2024
Objective: To determine how fracture clinic patients perceive the dangers of distracted driving.
Design: Analysis of patient perception subset data from the original DRIVSAFE study; a large, multicenter cross-sectional study, surveying fracture clinic patients about distracted driving.
Setting: Four Level 1 Canadian trauma center fracture clinics.
Improved mortality analysis in early-phase dose-ranging clinical trials for emergency medical diseases using Bayesian time-to-event models with active comparators.
Stat Med
August 2024
Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, Kansas, USA.
Emergency medical diseases (EMDs) are the leading cause of death worldwide. A time-to-death analysis is needed to accurately identify the risks and describe the pattern of an EMD because the mortality rate can peak early and then decline. Dose-ranging Phase II clinical trials are essential for developing new therapies for EMDs.
View Article and Find Full Text PDFLignin-derivable alternatives to bisphenol A with potentially undetectable estrogenic activity and minimal developmental toxicity.
Food Chem Toxicol
August 2024
Department of Animal and Food Sciences, University of Delaware, Newark, DE, 19716, USA. Electronic address:
Lignin-derivable bisguaiacols/bissyringols are viable alternatives to commercial bisphenols; however, many bisguaiacols/bissyringols (e.g., bisguaiacol F [BGF]) have unsubstituted bridging carbons between the aromatic rings, making them more structurally similar to bisphenol F (BPF) than bisphenol A (BPA) - both of which are suspected endocrine disruptors.
View Article and Find Full Text PDFBiomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study.
Am J Respir Crit Care Med
August 2024
School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton and National Institute for Health and Care Research Southampton Biomedical Research Centre, Southampton, United Kingdom.
The anti-IgE monoclonal antibody omalizumab is widely used for severe asthma. This study aimed to identify biomarkers that predict clinical improvement during 1 year of omalizumab treatment. One-year open-label Study of Mechanisms of action of Omalizumab in Severe Asthma (SoMOSA) involving 216 patients with severe (Global Initiative for Asthma step 4/5) uncontrolled atopic asthma (at least two severe exacerbations in the previous year) taking high-dose inhaled corticosteroids and long-acting β-agonists with or without maintenance oral corticosteroids.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!